cagrilintide vs cagrisema
updated
cagrilintide (tier B) vs cagrisema (tier B): what each is, why each got its grade, half-life and source counts side by side.
cagrilintide · tier B
novo's long-acting amylin analog. 11.8% standalone weight loss in the phase-3 REDEFINE-1 trial (10.8% earlier in phase 2). the filed product is the cagrisema combo, not the monotherapy.
tier rationale
B-tier because the standalone is investigational and its strongest published number (11.8% in the phase-3 REDEFINE-1 trial) trails the FDA-grade obesity drugs. the mechanism is real and the data is real, including a within-trial win over liraglutide in phase 2. but the program that reached an FDA filing is the cagrisema combination, not the monotherapy, and the dedicated RENEW monotherapy phase-3 is still running. S is reserved for approved or dominant-evidence compounds; A is reserved for compounds in wide clinical use. cagrilintide alone is neither yet.
cagrisema · tier B
semaglutide + cagrilintide. first fixed-dose GLP-1 + amylin combo. FDA review underway 2026.
tier rationale
B-tier because the drug is not FDA-approved yet. clinical evidence is drug-grade: phase-3 program across 4,600 patients, NEJM, NDA filed. S is reserved for compounds with a decision issued. on FDA approval (expected late 2026) this moves to S. could also move up if REDEFINE-11 or higher-dose escalation finally hits the 25% novo originally targeted.
at a glance
| cagrilintide | cagrisema | |
|---|---|---|
| tier | B | B |
| category | weight loss | weight loss |
| sources | 5 | 28 |
| claims evaluated | 6 | 7 |
| half-life | ~7 days | ~168 hours |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.